Portage Buys Tarus, Gaining Cancer Assets Targeting Immune Evasion
Acquisition valued at roughly $21m upfront for two clinical and two preclinical adenosine receptor antagonists.
Acquisition valued at roughly $21m upfront for two clinical and two preclinical adenosine receptor antagonists.